PBH (Prestige Consumer Healthcare) Growth Rank: 7 (As of Aug. 20, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBH Prestige Consumer Healthcare Inc PBH
69 GF Score
Price $50.52
GF Value $70.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prestige Consumer Healthcare Growth Rank?

Prestige Consumer Healthcare PBH -2.24% 69 Growth Rank is 7 as of Aug. 20, 2026, which is at its 10-year median of 7.00. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Prestige Consumer Healthcare has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Prestige Consumer Healthcare Growth Rank Related Terms

PBH vs BCRX, AMLX, SUPN: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prestige Consumer Healthcare Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Growth Rank distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's Growth Rank falls into.


PBH
69GF Score
Prestige Consumer Healthcare Inc PBH
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Prestige Consumer Healthcare (PBH) has a Growth Rank of 7 as of Aug. 20, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Prestige Consumer Healthcare and its competitors. This is near median its historical median of 7.00. Over the past decade, Prestige Consumer Healthcare's Growth Rank has ranged from 1.00 to 10.00.
Is Prestige Consumer Healthcare's Growth Rank too high?
Prestige Consumer Healthcare's current Growth Rank of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Growth Rank compare to BCRX and AMLX?
Prestige Consumer Healthcare's Growth Rank of 7 can be compared against companies in the Drug Manufacturers industry. Historically, Prestige Consumer Healthcare's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Prestige Consumer Healthcare and its competitors. Prestige Consumer Healthcare's current Growth Rank is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current Growth Rank is 7, which is near median its 10-year median of 7.00. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current Growth Rank is 7 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?

Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued. The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51. GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.

Key valuation signals for PBH:

  • Growth Rank: 7 (near median its 10-year median of 7.00)
  • GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prestige Consumer Healthcare Business Description

Other Exchanges PBV:Germany
Address 660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score

Get the complete analysis for PBH

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.52
Price
$70.51
GF Value